Tumor angiogenesis pathway

Tumor angiogenesis pathway refers to the collection of molecular mechanisms and cell signaling events that drive the formation of new blood vessels within tumor tissues, enabling sustained tumor growth and metastasis. This process is regulated by a variety of pro-angiogenic factors (e.g., vascular endothelial growth factor [VEGF], fibroblast growth factor [FGF], platelet-derived growth factor [PDGF], angiopoietins, and matrix metalloproteinases) and their receptors. Signaling pathways include VEGF/VEGFR, FGF/FGFR, PDGF/PDGFR, Angiopoietins/Tie2, and integrins, among others. These pathways coordinate endothelial cell activation, proliferation, invasion, migration, and the remodeling of the extracellular matrix. Tumor angiogenesis can occur via multiple mechanisms including sprouting angiogenesis, intussusceptive angiogenesis, vasculogenesis, vessel co-option, and vascular mimicry. Therapeutic targeting of angiogenesis aims to inhibit tumor growth by blocking these pathways with dedicated agents, though resistance and off-target effects are important clinical challenges[1][3][4][7][8][9]. The entry "Tumor angiogenesis pathway" is not a single molecule—thus, if structure requires a molecule/receptor, specific canonical forms would be VEGF receptor, FGF receptor, Angiopoietin/Tie2, etc., each of which is individually targeted by the drugs and mechanisms listed.

Other names

Angiogenesis pathwayTumor neovascularization pathwayCancer blood vessel formation

Inhibition of VEGF signaling and receptor activation; Blockade of FGF or PDGF pathways; Neutralization of angiopoietins (Ang1/Ang2) and Tie2 activation; Reduction of endothelial cell proliferation/migration; Suppression of matrix metalloproteinase activity and ECM remodeling